The first participant has been dosed in a large clinical trial testing TGM-312, a novel gene-silencing therapy designed to slow the progression of metabolic dysfunction-associated…

Children with Alagille syndrome who have lower blood levels of bile acids, the main component of the digestive fluid bile, have better long-term liver…

In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…